Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int
Status:
Completed
Trial end date:
2021-03-10
Target enrollment:
Participant gender:
Summary
This is a Phase I trial to determine the maximum tolerated dose/maximum feasible dose
(MTD/MFD) of a single infusion of FATE-NK100 via intra-peritoneal catheter in women with
recurrent ovarian, fallopian tube or primary peritoneal cancer meeting one of the following
minimal prior treatment requirement:
- Platinum resistant: may receive FATE-NK100 as 2nd line (as 1st salvage therapy).
Platinum resistant is defined as disease that has responded to initial chemotherapy but
demonstrates recurrence within a relatively short period of time (< 6 months) following
the completion of treatment.
- Platinum sensitive: may receive FATE-NK100 as 3rd line therapy (as 2nd salvage therapy).
Platinum sensitive is defined as the recurrence of active disease in a patient who has
achieved a documented response to initial platinum-based treatment and has been off
therapy for an extended period of time (≥ 6 months).